再程放疗联合贝伐珠单抗治疗复发高级别脑胶质瘤的疗效与安全性分析  

Efficacy and safety of re-radiotherapy combined with bevacizumab in treatment of recurrent high-grade glioma

作　　者：王宝红 倪春霞[1] 陈淑[1] 胡莉 张玺炜 高洪元 汪洋[3] WANG Bao-hong;NI Chun-xia;CHEN Shu(Department of Radiology,Shanghai Gamma Knife Hospital,Shanghai 200235,China)

机构地区：[1]复旦大学附属华山医院上海伽玛医院放疗科,上海200235 [2]上海市静安区中心医院(复旦大学附属华山医院静安分院)肿瘤科 [3]复旦大学附属华山医院放射治疗中心

出　　处：《临床神经外科杂志》2022年第4期392-395,共4页Journal of Clinical Neurosurgery

摘　　要：目的探讨再程放疗联合贝伐单抗治疗复发高级别脑胶质瘤的疗效与安全。方法回顾性分析31例复发高级别胶质瘤患者的临床资料,其中再程放疗联合贝伐单抗组(实验组)15例,单纯再程放疗组(对照组)16例。再程放疗处方剂量DT52~60 Gy,2 Gy/次,5次/周,共26~30次;贝伐单抗每次剂量300~400 mg、每3周1次。放疗中和放疗后1个月评估治疗不良反应;放疗后1个月评估治疗效果,随后每3个月评估1次。结果实验组的近期有效率66.7%,中位无进展生存期(PFS)7.9个月,平均总生存期(OS)12.7个月;对照组近期有效率31.3%,中位无进展生存期5.8个月,中位总生存期10.2个月。结论再程放疗联合贝伐单抗的近期有效率、PFS和OS比单纯放疗好,但差异没有达到显著性水平;两组的血液学毒性和神经系统不良反应对比,差异无统计学意义(P>0.05)。Objective To investigate the efficacy and safety of re-radiotherapy combined with bevacizumab in the treatment of recurrent high-grade glioma.Methods The clinical data of 31 patients with recurrent high-grade gliomas were analyzed retrospectively,including 15 in the retreatment group of radiotherapy combined with bevacizumab(experimental group)and 16 in the retreatment group of radiotherapy alone(control group).The prescribed total dose of re-radiotherapy was 52-60 Gy,2 Gy per fraction,5 times a week and 26-30 times in total.Bevacizumab was given at a dose of 300-400 mg once every 3 weeks.Adverse reactions were evaluated during radiotherapy and 1 month after radiotherapy.Treatment response was assessed 1 month after radiotherapy and then every 3 months.Results The short-term effective rate of the experimental group was 66.7%,the median progression free survival(PFS)was 7.9 months,and the average overall survival(OS)was 12.7 months.The short-term effective rate of the control group was 31.3%,the median PFS time was 5.8 months,and the median OS time was 10.2 months.Conclusions The short-term effective rate,PFS and OS of retreatment radiotherapy combined with bevacizumab are better than those of radiotherapy alone,but the difference is not significant.There was no significant difference in hematological toxicity and adverse reactions of nervous system between the two groups(P>0.05).

关 键 词：再程放疗 贝伐单抗 复发 高级别胶质瘤 

分 类 号：R739.41[医药卫生—肿瘤] R815.2[医药卫生—临床医学]